Results 151 to 160 of about 5,368 (169)

BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers

Cancers, 2023
Giorgia Castellani, Mariachiara Buccarelli, Maria Beatrice Arasi   +2 more
exaly  

RASopathy mutations provide functional insight into the BRAF cysteine-rich domain and reveal the importance of autoinhibition in BRAF regulation

Molecular Cell, 2022
Russell Spencer-Smith, Constance Agamasu, Daniel A Ritt   +2 more
exaly  

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy

ESMO Open, 2023
Mohamed A Gouda, Vivek Subbiah
exaly  

Vemurafenib: the first drug approved for BRAF-mutant cancer

Nature Reviews Drug Discovery, 2012
Gideon Bollag, James Tsai, Jiazhong Zhang   +2 more
exaly  

Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort

European Journal of Cancer, 2012
Lu Si, Yan Kong, Xiaowei Xu
exaly  

Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody

Acta Neuropathologica, 2011
David Capper, Matthias Preusser, Felix Sahm   +2 more
exaly  

Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

Cancer, 2011
Ben Tran, Scott Kopetz, Jeanne Tie
exaly  

Targeting Oncogenic BRAF: Past, Present, and Future

Cancers, 2019
Aubhishek Zaman, Trever G Bivona, Bivona Trever G   +2 more
exaly  

Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases

Acta Neuropathologica, 2011
David Capper, Anna S Berghoff, Aysegul Ilhan   +2 more
exaly  

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study

British Journal of Cancer, 2009
C Dive, Dive C
exaly